Clinical Research Directory

Inclusion Criteria: * Had \> 6 months ago a medial partial meniscectomy as confirmed by patient history and MRI * Is between age 30 and 75 years (inclusive) at the time of study treatment * Has neutral alignment ±5º of the mechanical axis, as measured from the angle formed by a line drawn from the center of the femoral head to the medial tibial spine and a line drawn from the medial tibial spine and the center of the ankle joint * Has ≥ 2 mm intact medial meniscal rim capable of being fitted with a NUsurface® device AND is also recommended for the baseline non-surgical (and, if likely to receive benefit, any injection) therapies to be administered in the study. * Is willing to be entered into either arm of the study: implanted with the NUsurface device OR treated with the recommended control arm therapies. * Is willing and able to attend all follow up visits, complete all study questionnaires, and undergo required X-ray and MRI schedule * Is able and willing to understand and sign the Informed Consent Form * Is able to read and understand the English language * Has a KOOS Pain of ≤ 75 (100 being the highest attainable and no pain) Exclusion Criteria: * Has a symptomatic knee because of a tear that could be addressed by a repeat partial meniscectomy leaving \> 4 mm of medial meniscus rim * Has evidence of a Outerbridge Grade IV cartilage loss on the medial tibial plateau or femoral condyle that potentially could contact a NUsurface implant (e.g., a focal lesion \> 0.5 cm2 correlating to a circular defect of \> 8 mm in diameter) * Has complete disruption of the posterior root attachment of the meniscus * Has lateral compartment pain and Grade III or Grade IV Outerbridge cartilage score in the lateral compartment * Has a varus or valgus knee deformity \> 5º requiring a tibial or femoral osteotomy * Has a laxity level of more than Grade II (IKDC), primary or secondary to an injury of the anterior cruciate ligament (ACL) and/or posterior cruciate ligament (PCL) and/or lateral collateral ligament (LCL) and/or medial collateral ligament (MCL) * Has significant trochlear dysplasia, patellar instability or symptomatic patellar misalignment * Has patellar compartment pain and Grade III or Grade IV Outerbridge cartilage score in the patellar compartment. * Compared to a normal knee, has obvious radiological evidence of medial femoral squaring, anatomical variance in the medial tibial plateau, or irregularly shaped cartilage surface * Had an ACL reconstruction performed \< 9 months prior to study treatment * Has a BMI \> 32.5 at the time of study treatment * Decides to receive (if eligible and an option) allograft medial meniscus transplantation * Received any type of prosthetic knee implant made of artificial non-resorbable plastic, metal or ceramic, not including the NUsurface® Meniscus Implant * Has a knee flexion contracture \> 10º * Has flexion \< 90º * Had a previous medial femoral condyle surgery (not including microfracture) or High Tibial Osteotomy (HTO) * Has insufficiency fractures or avascular necrosis of the medial compartment * Has an active infection or tumor (local or systemic) * Has any type of knee joint inflammatory disease including Sjogren's syndrome * Has neuropathic knee osteoarthropathy, also known as Charcot joint * Has any medical condition that does not allow possible arthroscopy of the knee * Has neurological deficit (sensory, motor, or reflex) * Is currently involved in another investigation of the lower extremity * Anticipates having another lower extremity surgery during the study period * Is contraindicated for hyaluronic acid injections (i.e., patients with known hypersensitivity \[allergy\] to hyaluronan \[sodium hyaluronate\] preparations); patients having knee joint infections or skin diseases or infections in the site of possible injections * Is contraindicated for corticosteroid injections (i.e., patients with allergy to any of the components or with idiopathic thrombocytopenic purpura) * Has received any corticosteroid knee injections ≤ 3 months prior to study treatment * Has chondrocalcinosis * Is on immunostimulating or immunosuppressing agents * Has ipsilateral or contralateral lower limb joint conditions that may affect ambulation or KOOS (e.g. have a leg length discrepancy \> 2.5 cm \[1 inch\], causing a noticeable limp) * Is a female who is lactating, expecting, or is intending to become pregnant during the study period * Is an active smoker * Is mentally incapacitated (incapable of appraising or controlling conduct) or have mental disability (e.g., dementia or Alzheimer's) * Is a prisoner * Is a patient who has economic incentive not to improve